According to a published statement by the DHS, "the SAFETY Act creates certain liability limitations for 'claims arising out of, relating to, or resulting from an act of terrorism' where qualified anti-terrorism technologies have been deployed. It also confers other benefits. Although there are many technologies that are important to protecting our homeland, the SAFETY Act 'Designation' and 'Certification' are designed to support effective technologies aimed at preventing, detecting,entifying, or deterring acts of terrorism, or limiting the harm that such acts might otherwise cause, and which also meet other prescribed criteria."

RSDL is a patented, broad spectrum skin decontamination product intended to remove or neutralize chemical warfare (CW) agents or T2 toxin from the skin. Originally developed for the Canadian Ministry of Defense, RSDL has since been adopted by several military services around the world, and is currently undergoing final configuration testing by the U.S. Department of Defense (DoD) for deployment with U.S. troops. The U.S Department of Defense authorized the sale of RSDL to first responder organizations in September of 2004. The US Food and Drug Administration (FDA) issued 510(k) clearance for RSDL in March of 2003.

Commenting on the announcement, Anthony A. Lombardo, President and CEO of E-Z-EM, said, "We are very pleased to have received designation and certification for RSDL under the SAFETY Act. The liability protections afforded under the law remove one potential barrier to sales of the product to first responder organizations. Though other potential liability issues remain in this market, we believe this is a very positive development for the product at a time when first responder organizations are assessing the proper role for RSDL in their disaster response plans."

About E-Z-EM, Inc.E-Z-EM is a publicly traded healthcare company founded in 1962, and has established itself as one of the most recognized brands in diagnostic imaging of the GI tract. From the first barium contrast systems introduced over 40 years ago, to today's advanced products for CT imaging and virtual colonoscopy, E-Z-EM has continually developed innovative imaging and diagnostic solutions for physicians treating GI diseases. E-Z-EM is also a respected contract manufacturer of specialized liquid products, and has been the exclusive global manufacturer of RSDL(TM) since 1996. In April of 2005, E-Z-EM completed the acquisition of all assets associated with RSDL, and now is the product's exclusive worldwide marketer.

The statements made in this document contain certain forward-looking statements. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions, are intended toentify such forward-looking statements. The forward-looking statements contained in this release may involve numerous risks and uncertainties, known and unknown, beyond the Company's control. Such risks and uncertainties include: the ability of the Company to develop its products, successful completion of DoD field testing by the U.S. government and placement of DoD order for RSDL, the impact on future sales of SAFETY Act designation and certification for RSDL, future orders of RSDL by first responder organizations, general military and first-responder market acceptance and sales of RSDL, future actions by the FDA or other regulatory agencies, overall economic conditions, general market conditions, price increases of raw materials and components, foreign currency exchange rate fluctuations as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Annual Report on its Form 10-K for the fiscal year ended June 3, 2006. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements, and investors are cautioned not to place undue reliance on the forward-looking statements included in this release.